Back to results
US 2025/0145668 A1Published application
Epitope focusing by variable effective antigen surface concentration
AssigneeCentivax, Inc.
InventorJacob E. Glanville
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCentivax, Inc.
InventorJacob E. Glanville
Estimating the term…
The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.
-32. (canceled)
A nucleic acid vaccine for eliciting an immune response in a subject, the nucleic acid vaccine comprising one or more nucleic acids that collectively encode at least six different antigens that each comprise a common target epitope, and wherein, upon administration of the vaccine, each individual antigen of the at least six different antigens is expressed at a level that if administered alone at the level of the individual antigen would elicit a weaker immune response to the common target epitope than the nucleic acid vaccine comprising the one or more nucleic acids that collectively encode at least six different antigens.
Dependencies are inferred from the claim text.